Catalio Capital Management

Imbria Pharmaceuticals, Inc. is a clinical-stage pharmaceuticals company based in Boston, Massachusetts, founded in 2018. The company specializes in developing innovative therapies aimed at addressing cardiometabolic disorders by enhancing or restoring cellular energy production. Imbria's research focuses on the mechanisms underlying these conditions, particularly in areas such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction. By translating scientific insights into practical treatments, Imbria Pharmaceuticals aims to meet significant unmet medical needs and improve the lives of patients affected by these life-altering disorders. Through its commitment to understanding cellular metabolism and mitochondrial function, the company works to advance healthcare solutions in the cardiometabolic space.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.

Aviceda Therapeutics is a late-stage, pre-clinical biotechnology company focused on developing innovative treatments for glyco-immune diseases. By leveraging glycobiology and a proprietary cell-based high-throughput screening platform, the company aims to create next-generation immunomodulators that target the innate immune system and address chronic non-resolving inflammation. Aviceda's product pipeline includes candidates for a variety of conditions, such as eye diseases, fibrosis, neurology, and oncology. Key products under development include AVD-104, AVD-302, and AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma, as well as AVD-601, AVD-701, and AVD-801 targeting oncology, neurology, and fibrosis. Through its advanced technologies and biological insights, Aviceda seeks to provide breakthrough glycol-therapeutics that improve patient outcomes.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

Orasis Pharmaceuticals Ltd is focused on developing innovative treatments for presbyopia, a common age-related vision condition. Founded in 2015 and based in Herzliya, Israel, the company has developed CSF-1, a corrective eye drop designed to improve near visual acuity through pupil modulation. This product aims to enhance the quality of life for individuals with presbyopia by alleviating the need for reading glasses. CSF-1 repurposes existing, well-studied molecules to ensure its effectiveness while prioritizing safety, comfort, and ease of use for patients. By providing a noninvasive treatment option, Orasis Pharmaceuticals offers a promising solution for those struggling with the symptoms of presbyopia.

Orasis Pharmaceuticals Ltd is focused on developing innovative treatments for presbyopia, a common age-related vision condition. Founded in 2015 and based in Herzliya, Israel, the company has developed CSF-1, a corrective eye drop designed to improve near visual acuity through pupil modulation. This product aims to enhance the quality of life for individuals with presbyopia by alleviating the need for reading glasses. CSF-1 repurposes existing, well-studied molecules to ensure its effectiveness while prioritizing safety, comfort, and ease of use for patients. By providing a noninvasive treatment option, Orasis Pharmaceuticals offers a promising solution for those struggling with the symptoms of presbyopia.

Superluminal Medicines is a generative biological and chemical company accelerating new possibilities in drug discovery and development. Its platform quickly creates candidate-ready compounds using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. They leverage cutting-edge computational and machine-learning techniques to accelerate identifying and optimizing novel drug candidates. Their approach combines high-throughput experimental data with advanced algorithms to uncover therapeutic compounds faster and more efficiently than traditional methods.

Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By leveraging self-supervised learning and integrating human multimodal data, the company aims to enhance the effectiveness and personalization of cancer therapies, thereby improving patient outcomes in oncology.

Imperative Care, Inc. is dedicated to enhancing the speed and effectiveness of acute stroke treatment through innovative medical technologies. Founded in 2015 and based in Campbell, California, the company has developed a range of solutions aimed at addressing critical needs in stroke care. Among its offerings is the Large Distal Platform, a large diameter catheter designed to reach treatment sites for both ischemic and hemorrhagic strokes. Complementing this is the ZOOM Aspiration System, a comprehensive solution that works in conjunction with the Large Distal Platform and includes various trackable reperfusion catheters for effective clot removal. By advancing stroke treatment technologies, Imperative Care aims to improve patient outcomes and optimize recovery processes for those affected by strokes.

InSightec Ltd. specializes in developing and distributing the Exablate platform, which employs MR-guided focused ultrasound technology for non-invasive medical treatments in oncology and gynecology. The company offers solutions such as Exablate Neuro, designed for personalized thalamotomy to address movement disorders and pain without invasive surgery, and a thermal ablation technique for the treatment of uterine fibroids, which alleviates symptoms while minimizing damage to surrounding tissues. Founded in 1999 and headquartered in Tirat Carmel, Israel, InSightec has expanded its presence globally with operations in Europe, Asia, and the Americas. The Exablate system has received various regulatory approvals, including CE marks and FDA approval, and has been recognized with multiple innovation awards for its contributions to healthcare. In addition to its medical devices, InSightec provides clinical training, business support, maintenance, and customer services to healthcare facilities using its technology.

Avava is a developer of advanced 3D precision laser treatment technology aimed at enhancing skin quality for patients globally. The company focuses on addressing skin conditions such as melasma and post-inflammatory hyperpigmentation, allowing healthcare providers to offer effective tissue treatments. By pioneering precision skin therapy, Avava seeks to improve the overall quality of life for individuals struggling with these skin concerns.

PinkDx is a biotechnology company.

ARTARA THERAPEUTICS is a clinical-stage healthcare company focused on developing transformative therapies for individuals with rare and specialty diseases. Its lead program, TARA-002, is an investigational cell therapy designed to treat lymphatic malformations and non-muscle invasive bladder cancer. Additionally, the company is advancing intravenous choline chloride, an investigational phospholipid substrate replacement therapy aimed at addressing intestinal failure-associated liver disease. Based in New York, ARTARA THERAPEUTICS is dedicated to providing innovative solutions for patients with limited treatment options, leveraging a team that values creativity and diverse perspectives to expedite the development of its therapies.

Clasp Therapeutics is focused on advancing cancer treatment through its innovative immunotherapeutics platform. The company develops precision medicines designed to enhance the immune system's ability to identify and eliminate challenging tumors that possess common driver mutations, irrespective of the tumor type. By enabling the targeting of cancer-specific markers, Clasp Therapeutics aims to allow for precise and selective destruction of tumor cells, thereby improving therapeutic outcomes in the field of immuno-oncology.

Roshal Imaging Services is a provider of on-site and portable diagnostic Vascular and General body (Ob/Gyne) ultrasound services. The company was founded in 2005 and is based in Katy, Texas, United States.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

OnCusp Therapeutics is a biopharmaceutical company focused on developing innovative oncology therapies aimed at improving treatments for cancer patients worldwide. Founded by Bing Yuan, Eric Slosberg, and Andy Fu, the company is dedicated to translating cutting-edge research into clinical applications. It specializes in advancing preclinical drug candidates to the clinical proof-of-concept stage, enabling a swift transition into global early clinical development. By prioritizing this process, OnCusp Therapeutics aims to accelerate the innovation of oncology medications, ultimately providing critical support and hope to those affected by cancer.

Lassen Therapeutics specializes in developing monoclonal antibodies aimed at treating fibrosis, rare diseases, and oncology. The company’s primary candidate, LASN01, targets the IL-11 receptor alpha, a critical component in the IL-6 family of cytokines. IL-11 is a significant mediator of fibrosis and plays an essential role in tumor growth and the organization of the tumor microenvironment. By blocking IL-11's activity, Lassen Therapeutics seeks to provide more effective treatment options compared to traditional approaches that target other factors like TGF-β and CTGF. Through innovative antibody technologies, the company aims to deliver breakthrough therapeutics that improve the lives of patients facing serious health challenges.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Sanguine is focused on enhancing translational biomedical research by facilitating patient participation. The company offers tools and concierge services that enable patients to engage in medical research from the comfort of their homes, promoting transparency and communication throughout the process. By prioritizing respectful patient support and appropriate compensation, Sanguine aims to improve the overall patient experience and ensure that research biospecimens are more impactful. Through these efforts, Sanguine seeks to bridge the gap between patients and researchers, empowering individuals to contribute directly to the development of personalized medicines and new treatments.

Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.

Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.

Georgiamune is an immunotherapy company dedicated to advancing oncology treatments. The firm specializes in next-generation immunotherapeutic and homeostatic therapies aimed at addressing cancer and autoimmune diseases. By focusing on innovative approaches, Georgiamune seeks to enhance patient recovery from cancer, contributing to significant breakthroughs in the field of immunotherapy.

Volastra Therapeutics, Inc. is a biotechnology company based in New York that focuses on developing therapies for metastatic cancers. Founded in 2019, the company utilizes a library of organoids derived from metastatic cancer samples to understand tumor spread and create targeted therapeutic strategies aimed at chromosomal instability. By integrating artificial intelligence, bioinformatics, and proprietary imaging techniques, Volastra identifies cancers at higher risk of metastasis, allowing healthcare professionals to select appropriate patients for therapy and improve treatment outcomes. Through its innovative approach, Volastra seeks to advance the understanding and management of metastatic diseases.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Spiral Therapeutics, Inc. is a clinical-stage pharmaceutical company based in San Francisco, California, specializing in the development of therapies for inner ear disorders. Founded in 2016, the company focuses on delivering innovative drug therapies that target acute and subacute hearing loss, as well as balance disorders stemming from neurodegenerative, inflammatory, or vascular causes. By utilizing a platform that ensures the right medications are delivered to the appropriate site for the necessary duration, Spiral Therapeutics aims to provide effective treatments for individuals suffering from hearing disorders, ultimately enhancing their quality of life.

Perceive Biotherapeutics is a biotechnology company focused on developing innovative ophthalmic therapeutics aimed at treating various eye diseases. The company leverages novel protective biologies to create a diverse pipeline of therapeutic assets that target significant causes of irreversible blindness. By utilizing multiple therapeutic modalities, Perceive Biotherapeutics seeks to provide medical professionals with effective solutions for improving eye health and preventing vision loss.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

Sickbay is a healthcare services company that offers a comprehensive software platform designed to enhance patient monitoring and analytics. This platform allows healthcare professionals to access complete patient histories, automate documentation, and create scalable teleICUs and command centers. By continuously collecting data from various medical devices, Sickbay's solutions improve alarm management, reduce unnecessary alarm noise at the patient level, and ensure that critical alarms reach care providers effectively. Additionally, Sickbay engages in the wholesale marketing of FDA-authorized nutritional supplements, catering to the needs of hospital professionals, medical offices, and healthcare workers. Founded in 1999, Sickbay emphasizes the importance of informed, data-driven decision-making in patient care.

Haystack Oncology is an oncology company that specializes in liquid biopsy diagnostic technology aimed at improving cancer treatment strategies and patient outcomes. By utilizing advanced circulating tumor DNA detection methods, the company enhances the diagnosis of minimal residual disease, allowing for more informed therapy decision-making. Their technology focuses on identifying tumor-specific markers through blood samples, which facilitates the early detection of recurrent disease and offers increased sensitivity in monitoring residual disease post-treatment. This innovation enables healthcare teams to access cutting-edge liquid biopsy tools, thereby transforming the management of cancer and significantly improving patient care.

Proto Axiom is an incubator based in Melbourne, Australia, established in 2021. The company focuses on enhancing the country's biotechnology sector by fostering the development of innovative drug and medical equipment technologies. Recognizing that Australia produces significant intellectual property in these fields but struggles with downstream commercialization, Proto Axiom aims to retain this valuable intellectual property within the country by developing preclinical expertise and supporting local ventures. Through its initiatives, the firm seeks to create job opportunities and bolster the domestic biotechnology landscape.

Fractyl Health, based in Lexington, Massachusetts, specializes in developing innovative medical device solutions for metabolic diseases, particularly type 2 diabetes and obesity. The company’s primary offering, Revita DMR, is a minimally invasive therapy that utilizes hydrothermal ablation to rejuvenate the duodenal lining, which can become compromised due to high-fat and high-sugar diets. By focusing on durable disease-modifying therapies rather than just symptomatic management, Fractyl Health aims to address the underlying causes of metabolic diseases, improving patient outcomes and reducing healthcare burdens. Founded in 2010 and originally named MedCatalyst, Inc., the company envisions a future where less invasive, device-based therapies provide effective solutions for large populations affected by metabolic disorders.

Cartography Biosciences is a biotechnology company focused on developing cancer therapies through precision medicine. The company has created a platform-based cell therapy that utilizes single-cell analysis to identify innovative CAR-T targets. This approach allows for the design of cancer immunotherapies tailored to the safest and most effective targets. By combining molecular biology and computational methods, Cartography enables clients to advance their studies in the development of these targeted treatments, aiming to improve outcomes for cancer patients.

Xilis, Inc. is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. It specializes in developing advanced organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. The company's flagship platform, XilisµO, facilitates rapid diagnostics and personalized drug screening while providing scalable, patient-derived models for high-throughput drug discovery. This technology supports physicians and pharmaceutical companies in creating tailored treatments by enabling effective drug screening, ultimately contributing to more precise and cost-efficient cancer therapies.

Anagenex is a seed stage biotechnology company focused on advancing drug discovery through its innovative platform. The company aims to tackle challenging pharmaceutical targets by utilizing a technology that combines machine learning with DNA-encoded libraries. This approach allows for the rapid analysis of compounds and the generation of extensive data sets, facilitating parallel biochemical experiments. By leveraging proprietary artificial intelligence models, Anagenex enables researchers to efficiently develop new small molecule drugs for medically significant applications.

Sickbay is a healthcare services company that offers a comprehensive software platform designed to enhance patient monitoring and analytics. This platform allows healthcare professionals to access complete patient histories, automate documentation, and create scalable teleICUs and command centers. By continuously collecting data from various medical devices, Sickbay's solutions improve alarm management, reduce unnecessary alarm noise at the patient level, and ensure that critical alarms reach care providers effectively. Additionally, Sickbay engages in the wholesale marketing of FDA-authorized nutritional supplements, catering to the needs of hospital professionals, medical offices, and healthcare workers. Founded in 1999, Sickbay emphasizes the importance of informed, data-driven decision-making in patient care.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Octant Bio is a biotechnology company focused on developing synthetic technology aimed at enhancing health and treating diseases. The company employs a platform that integrates synthetic biology, genome engineering, next-generation sequencing, and computational tools to measure the activity of thousands of receptor pathways in human cells. This advanced technology allows scientists to utilize machine learning techniques to engineer small molecules capable of interacting with multiple receptors, thereby creating new possibilities for the treatment of complex diseases.

Pheast Therapeutics is a cancer immunotherapy company founded in 2020 and based in Palo Alto, California. The company specializes in developing innovative checkpoint therapies aimed at activating the innate immune system to combat cancer. Its primary focus is on creating immunotherapies that target macrophage checkpoints, which are crucial for enabling macrophages to effectively eliminate tumors in ovarian and breast cancers. By blocking these immune checkpoints, Pheast Therapeutics aims to enhance the likelihood of patient survival and advance treatment options within the healthcare sector.

Celsius Therapeutics is a biotechnology company focused on developing precision medicines for patients with cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a team of scientists, technologists, computational biologists, clinicians, and drug hunters. Utilizing single-cell genomic analysis and machine learning techniques, Celsius Therapeutics aims to discover and create innovative therapies that can lead to significant improvements in patient outcomes. The company's research efforts are centered on identifying new drug candidates that address unmet medical needs in the therapeutic landscape.

Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-cell therapies designed to eradicate tumors.

PrognomiQ is a technology company dedicated to advancing early disease detection and treatment, particularly for cancer and other complex diseases. By harnessing multi-omics data, including proteomic, genomic, and metabolomic information, the company aims to enhance understanding and management of health conditions. PrognomiQ's innovative approach allows for the development of advanced medical test products that improve diagnostic capabilities and recurrence monitoring, ultimately seeking to enhance patient outcomes. Through its focus on integrating diverse health data, PrognomiQ is committed to transforming how medical practitioners approach disease detection and treatment.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Sherlock Biosciences is a biotechnology company based in Cambridge, Massachusetts, focused on developing molecular diagnostic solutions. Incorporated in 2018, the company utilizes cutting-edge engineering biology tools, including CRISPR and synthetic biology, to create innovative diagnostic platforms. Its primary products include SHERLOCK, a CRISPR-based method for detecting and quantifying specific genetic sequences, and INSPECTR, a synthetic biology-based diagnostics platform. These technologies aim to provide rapid, accurate, and affordable results across various applications, including precision oncology, infection identification, food safety, at-home testing, and disease detection. By leveraging these advanced tools, Sherlock Biosciences addresses the need for effective diagnostics in both high and low-resource settings.

Satellite Bio is a company that specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It is dedicated to developing a therapeutic platform aimed at creating innovative cell therapies to address complex diseases. The company’s primary focus is on the design and implementation of proprietary, off-the-shelf, implantable satellite organs, which serve as living therapeutic solutions. These satellite organs are intended to improve the lives of millions of patients suffering from serious health conditions.

Septerna is a biotechnology company focused on discovering and advancing novel small-molecule medicines that target G protein-coupled receptors (GPCRs). The company aims to improve patient outcomes by integrating innovative drug discovery technologies with GPCR drug targets. Utilizing its Native Complex platform, Septerna facilitates industrial-scale drug discovery through advanced screening technologies and structure-based drug design. This approach enables medical researchers to efficiently identify treatments for a variety of diseases.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

Hyperfine is a medical device company that developed Swoop, the first FDA-cleared point-of-care MRI system designed to enhance patient access to diagnostic imaging. Swoop operates at a lower magnetic field strength than traditional MRI machines, producing high-quality images quickly and efficiently. This portable system can be easily wheeled to a patient's bedside, plugged into a standard electrical outlet, and operated via an iPad, making it suitable for various clinical environments such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of MRI devices and service sales, which include subscriptions for bundled devices, maintenance, and software. By providing rapid imaging capabilities at a fraction of the cost of conventional MRIs, Hyperfine aims to facilitate timely diagnoses and treatments for patients, regardless of their location or resources.

Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.

Bayesian Health Inc. is a digital health company based in New York, established in 2016. It specializes in an AI-driven platform that enhances patient monitoring by assessing illness severity and detecting changes in acuity. This technology integrates with hospital electronic medical records (EMR), allowing clinical staff and hospital leadership to access real-time data and insights. The platform provides actionable early detection alerts and supports decision-making in complex clinical environments, ultimately optimizing patient care throughout their hospital stay. By leveraging existing investments in EMR systems, Bayesian Health enables healthcare providers to make informed, data-driven decisions that improve safety and efficiency in patient management.

Xilis, Inc. is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. It specializes in developing advanced organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. The company's flagship platform, XilisµO, facilitates rapid diagnostics and personalized drug screening while providing scalable, patient-derived models for high-throughput drug discovery. This technology supports physicians and pharmaceutical companies in creating tailored treatments by enabling effective drug screening, ultimately contributing to more precise and cost-efficient cancer therapies.

Enveda Biosciences is a biotechnology company focused on drug discovery through the exploration of chemical diversity found in nature. Utilizing AI-powered tools, the company develops a robust database of chemical molecules derived from living organisms. Enveda's platform integrates machine learning, metabolomics, and robotics to analyze natural samples for their chemical structures and biological activities. This innovative approach allows for the efficient identification of potential new medicines, including antibiotics and hypotensives, without the need for isolating individual compounds or conducting extensive experiments. By harnessing nature's hidden chemistry, Enveda aims to accelerate the development of novel therapeutics for the healthcare industry.

Volastra Therapeutics, Inc. is a biotechnology company based in New York that focuses on developing therapies for metastatic cancers. Founded in 2019, the company utilizes a library of organoids derived from metastatic cancer samples to understand tumor spread and create targeted therapeutic strategies aimed at chromosomal instability. By integrating artificial intelligence, bioinformatics, and proprietary imaging techniques, Volastra identifies cancers at higher risk of metastasis, allowing healthcare professionals to select appropriate patients for therapy and improve treatment outcomes. Through its innovative approach, Volastra seeks to advance the understanding and management of metastatic diseases.

Immunai Inc. is a biotechnology company that specializes in developing an artificial intelligence-based immune profiling platform aimed at enhancing drug development and improving disease detection, diagnosis, and treatment. The company utilizes single-cell genomics and machine learning algorithms to conduct high-resolution profiling of the immune system, generating valuable biological insights that facilitate research and development. Immunai's platform focuses on biomarker discovery, enabling the identification of how immune cells respond to various conditions, and supports the development of therapies for oncology and autoimmune disorders. Established in 2018 and headquartered in New York City, Immunai also maintains offices in San Francisco and Tel Aviv, collaborating with academic institutions, biopharmaceutical firms, and biotechnology companies to advance its mission of mapping the immune system and its functions.

Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

Paige, founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializes in computational pathology products that enhance cancer diagnostics. The company has developed a platform utilizing advanced deep learning algorithms to improve diagnostic stratification and cancer detection, particularly for breast and prostate cancers. This innovative technology aims to empower patients and their care teams to make informed treatment decisions by providing pathologists with critical insights for more accurate diagnoses. Paige's user-friendly platform minimizes the burden on IT resources while ensuring patient safety and data privacy. As a pioneer in the field, Paige has achieved FDA breakthrough designation for its computational pathology products, positioning itself at the forefront of transforming pathology workflows and increasing diagnostic confidence.

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, with an additional office in Boston, Massachusetts. Founded in 1999, the company specializes in developing precision cancer therapeutics, particularly next-generation immunotherapies. Sensei's proprietary drug discovery platform, ImmunoPhage, focuses on understanding the tumor microenvironment to create novel biologics that target tumor-specific antigens and activate both the innate and adaptive immune systems. The company is working on a range of investigational product candidates, including SNS-101, SNS-102, SNS-103, and SNS-20, which aim to address unmet needs in cancer treatment by selectively disabling immunosuppressive signals or activating immunostimulatory signals within the tumor microenvironment. Through its innovative approach and collaboration with experts in biology, immunology, and oncology, Sensei Biotherapeutics seeks to transform cancer treatment and improve outcomes for patients.

Faze Medicines is a biotechnology company founded in 2020 and located in Cambridge, Massachusetts. The company focuses on developing small molecule drugs that target the underlying mechanisms of disease pathology, with initial therapeutic efforts directed towards conditions such as amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). Faze Medicines employs advanced screening and proteomics techniques to explore biomolecular condensate interaction networks, which aids in the identification and development of novel therapeutics. Through its innovative approach, Faze aims to provide effective treatments for patients suffering from these challenging diseases.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

Glympse Bio, Inc. is a diagnostic company based in Cambridge, Massachusetts, that focuses on developing modular nanoparticle sensors for noninvasive disease monitoring. Founded in 2015, the company creates engineered diagnostic agents designed to interrogate the body for specific disease states, subsequently conveying this information through urine analysis. This innovative approach facilitates the monitoring of various conditions, including fibrosis, cancer, immunology, and infectious diseases, while also assessing drug responses. Glympse Bio's flagship product, Glympse Inside, serves as a pan-disease platform aimed at revolutionizing how diseases are monitored and treated. The technology was initially developed at MIT and is supported by a team of experts in nanomedicine and biomedical engineering.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics to address significant unmet medical needs in areas such as inflammatory diseases, autoimmune disorders, and immune-oncology. The company utilizes a proprietary platform to create first-in-class biologics that feature customized and highly homogeneous human glycans assembled onto glycoproteins in a site-specific manner. This approach enables healthcare companies to gain insights into the role of glycans in human health and disease, ultimately advancing the development of novel treatments.